What is the latest update in the cell therapy market?

The cell therapy market is moving fast, and Q1 2026 brought billion-dollar acquisitions, new FDA flexibility, and growing proof that CAR-T can work far beyond cancer.

This blog post is our running summary of the most important updates in the cell therapy market, and we refresh it every quarter so you always have the latest picture.

The cell therapy market is now worth an estimated $6-7 billion in 2026, with CAR-T therapies generating over $4 billion in annual revenue across seven FDA-approved products.

And if you want to better understand this new industry, you can download our pitch covering the cell therapy market.

Summary table of the most important updates in the cell therapy market

We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.

We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.

We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.

You can also get all the latest market news for the month here.

News	Category	Date	Source
Gilead moved to fully own anito-cel in a $7.8B Arcellx takeover	M&A	Feb 23, 2026	Gilead
FDA loosened key manufacturing rules for cell therapies	Regulations & Policies	Jan 11, 2026	FDA
Lilly paid up to $2.4B to jump into in vivo CAR-T	M&A	Feb 9, 2026	Lilly
Orca Bio raised $250M to prepare for a near-term cell therapy launch	Fundraisings	Jan 9, 2026	Orca Bio
Cellares raised $257M to scale automated cell therapy manufacturing	Fundraisings	Jan 28, 2026	Cellares
Autoimmune CAR-T got one of the year's clearest clinical proofs	Breakthrough	Jan 7, 2026	Nature Medicine
Wugen won FDA Breakthrough status for off-the-shelf CAR-T in T-cell cancers	Product launches	Jan 21, 2026	Wugen
Caribou got RMAT for an allogeneic BCMA CAR-T in myeloma	Product launches	Mar 31, 2026	Business Insider
Eureka got RMAT for a solid-tumor CAR-T in liver cancer	Product launches	Jan 12, 2026	Eureka
Cellares and City of Hope teamed up to automate solid-tumor CAR-T production	Partnerships	Jan 8, 2026	Cellares
Orca-T posted stronger survival than standard transplant approaches	Success metrics	Feb 5, 2026	BusinessWire
Cabaletta set up a possible autoimmune CAR-T registration path for 2027	Company updates	Mar 23, 2026	Cabaletta Bio

How is the cell therapy market doing now?

How do we define the cell therapy market?

We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.

We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.

We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.

This is also the definition we use in our report covering the cell therapy market.

How big is the cell therapy market in 2026?

Based on verified company revenues and bottom-up calculations, we estimate the cell therapy market at $6-7 billion in 2026, with CAR-T products making up roughly $4.8-5.2 billion of that total.

This is not a random guess, if you want to know how we have come up with this estimate, you can read our cell therapy market size analysis here.

To put that in perspective, the cell therapy market is about the same size as the global insulin pump market ($6.5 billion) and roughly one-tenth of the broader oncology drug market ($200+ billion).

The cell therapy market is still early-stage (maturity score of 35/100) with only seven FDA-approved CAR-T products, but it is already highly competitive because Gilead and Bristol Myers Squibb control over 70% of approved CAR-T revenue.

How fast will the cell therapy market grow in the future?

A realistic growth rate for the cell therapy market is around 22% per year, which is the median estimate from the research firms whose definitions best match ours.

At that pace, the cell therapy market should reach roughly $15 billion by 2030, and could grow to about $48 billion by 2036, which would be a 7x increase from today.

If that happens, the cell therapy market in 2036 would be roughly equivalent to today's combined global CAR-T and checkpoint inhibitor markets, putting it on par with some of the biggest segments in oncology.

What does current funding activity look like in the cell therapy market?

Our team, who continually updates our cell therapy market pitch deck, is keeping a close eye on the market and tracking key signals.

One of those signals is fundraising activity across startups. Each month, we refresh this page with a list of startups of the cell therapy market that have raised funding, and we also publish a quarterly analysis here.

Is funding momentum accelerating or cooling in the cell therapy market these days?

Q1 2026 saw several very large cell therapy fundraising rounds, including $257 million for Cellares, $250 million for Orca Bio, and $140 million for MEDIPOST, which suggests funding momentum is strong for late-stage and manufacturing-focused companies.

This is a notable improvement from the broader trend of 2024, when cell and gene therapy venture capital funding had dropped 83% from its 2021 peak of $8.2 billion down to just $1.4 billion.

The average deal size in Q1 2026 skewed very large, with the top three rounds all exceeding $140 million, which points to investor appetite concentrating on companies that are closest to commercialization or solving manufacturing bottlenecks.

Which categories and business models are attracting capital in the cell therapy market?

These categories and business models of the cell therapy market are receiving important fundraising currently:

• Cellares raised $257 million for automated cell therapy manufacturing, showing that investors see factory-scale production as a major value driver.
• Orca Bio raised $250 million for launch readiness of its high-precision cell therapy, signaling strong confidence in near-term FDA approval.
• MEDIPOST raised $140 million for a late-stage allogeneic cell therapy trial, proving that non-CAR-T, off-the-shelf cell therapies can still attract large rounds.

The common thread is clear: cell therapy investors in Q1 2026 are backing companies that are either close to market or solving the manufacturing problems that hold the whole field back.

Who's writing the most checks in the cell therapy market?

These investors are being very active when it comes to fundraising in the cell therapy market:

• BlackRock, the world's largest asset manager, co-led Cellares' $257 million Series D, showing that mainstream institutional capital is now flowing into cell therapy manufacturing.
• Eclipse Ventures, a deep-tech venture firm, also co-led Cellares' round, continuing its focus on companies that combine hardware and software to transform how things are built.

The entry of major institutional investors like BlackRock into cell therapy infrastructure suggests the market is maturing beyond early biotech risk and toward scalable industrial plays.

Any big acquisitions or IPOs in the last three months in the cell therapy market?

These are the big acquisitions and IPOs that happened recently in the cell therapy market:

• Gilead announced a $7.8 billion acquisition of Arcellx to gain full control of anito-cel, a late-stage BCMA CAR-T therapy for multiple myeloma.
• Eli Lilly agreed to pay up to $2.4 billion for Orna Therapeutics, which brings an in vivo CAR-T program aimed at autoimmune disease.

Over $10 billion in cell therapy M&A in a single quarter tells you that large pharma companies would rather buy proven cell therapy assets than build them from scratch.

How are companies in the cell therapy market performing overall?

We are watching this market everyday, because we need to constantly update our pitch deck. Here is a couple of things we have noticed.

Are there any standout success metrics or financial results in the cell therapy market?

Yes, Q1 2026 brought one notable clinical performance update in the cell therapy market:

• Orca Bio presented new data showing Orca-T delivered better overall survival, relapse-free survival, and GVHD-free relapse-free survival than standard transplant approaches, with 100% of products distributed within 70 hours.

Good clinical outcomes paired with reliable manufacturing and logistics is exactly the combination that cell therapy investors want to see right before a product launch.

Have there been any major partnerships in the cell therapy market?

Yes, one notable cell therapy partnership stood out in Q1 2026:

• Cellares and City of Hope teamed up to automate manufacturing for CARpool, a glioblastoma CAR-T program, aiming to remove production bottlenecks before clinical scaling.

This partnership shows that leading cell therapy research centers are bringing in manufacturing automation partners early, before scale becomes a problem.

Have there been any notable technology or infrastructure breakthroughs in the cell therapy market?

Yes, Q1 2026 delivered one of the most important clinical breakthroughs for the cell therapy market in recent memory:

• A Nature Medicine paper reported results from the CASTLE trial of Zorpo-cel in severe autoimmune disease, where all 24 patients achieved drug-free and steroid-free remission beyond six months with no high-grade safety events.

This is one of the strongest pieces of evidence yet that CAR-T cell therapy can expand from cancer into the much larger autoimmune disease market.

Have any companies restructured or shifted pricing or business model in the cell therapy market?

We did not track any major restructuring, pricing changes, or business model shifts during Q1 2026 in the cell therapy market.

Are there any other notable wins or successes in the cell therapy market?

Yes, several cell therapy companies received important regulatory wins in Q1 2026:

• Wugen won FDA Breakthrough Therapy Designation for Sofi-cel, an off-the-shelf CAR-T for T-cell cancers, with a pivotal study already ongoing.
• Caribou Biosciences received RMAT designation for CB-011, an allogeneic BCMA CAR-T for myeloma, with early data showing 92% response rates in a small cohort.
• Eureka Therapeutics received RMAT designation for ECT204, a solid-tumor CAR-T targeting liver cancer, one of the hardest areas for cell therapy.
• Cabaletta Bio outlined a path to a 2027 BLA submission for rese-cel in autoimmune myositis, with automated manufacturing already underway through a partnership with Cellares.

Three FDA designations plus one clear registration path in a single quarter shows that regulators are actively supporting the next wave of cell therapy products.

What is the overall sentiment in the cell therapy market right now?

Are there any notable recent opinion pieces, thought leadership about the cell therapy market?

Yes, one major piece of thought leadership stood out in Q1 2026:

• Nature Biotechnology published a feature in March 2026 identifying autoimmune B-cell depletion as a dealmaking hotspot, noting that investors and acquirers are actively choosing between in vivo CAR-T and T-cell engagers for this space.

When a publication as respected as Nature Biotechnology calls something a dealmaking hotspot, it usually means the capital and M&A flow are about to accelerate even further.

Are there any interesting and recent market research reports about the cell therapy market?

We did not come across any standalone market research reports published during Q1 2026 in the cell therapy market that are worth highlighting separately here.

Have there been any regulatory changes, policy updates, or new compliance requirements in the cell therapy market?

Yes, one major regulatory update happened during Q1 2026 in the cell therapy market:

• The FDA announced increased flexibility in manufacturing requirements for cell and gene therapies on January 11, 2026, making it easier for companies to adjust their production processes where the science supports it.

This is a big deal because manufacturing is one of the biggest bottlenecks in the cell therapy market, and a more flexible FDA approach can reduce delays, lower costs, and speed up filings across the board.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.